Treprostinil Sodium
Treatment of primary pulmonary arterial hypertension or pulmonary arterial hypertension associated with connective tissue disease, in patients with disease of WHO Functional Class III or IV severity.
Access path
- Nov 2005Recommended
Evidence: RCT → Meta-analysis
- Nov 2005Recommended
Evidence: RCT → Meta-analysis
- PBS listing · Authority Required
Cost-effectiveness
Cost-minimisation analysis; no ICER calculated
The choice of the cost-minimisation approach was considered valid by the PBAC. PBAC · 2005
Decision context
PopulationPatients with primary pulmonary arterial hypertension or pulmonary arterial hypertension associated with connective tissue disease, excluding congenital heart disease, chronic thromboembolic pulmonary hypertension, and portopulmonary hypertension, with WHO Functional Class III or IV severity.
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Nov 2005 | Recommended | bosentan | — | RCT · 6-minute walk test, survival |
| Nov 2005 | Recommended | bosentan | — | Meta-analysis · 6MWD |
Similar precedents
Regulatory · TGA
Label narrower than PBS population — PBAC restricts to primary PAH or CTD-associated PAH; TGA label includes all PAH types without etiology specification.